MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. MagForce is forging new paths in order to treat tumors from within with our NanoTherm® therapy. NanoTherm® therapy is a relatively new procedure for the focal treatment of solid tumors. In a nutshell: Magnetic nanoparticles are introduced either directly into the tumor or into the resection cavity wall. These particles are subsequently heated by an alternating magnetic field, thus destroying the cancer cells. NanoTherm® therapy is the first and only nanotechnology-based therapy with European approval for the treatment of brain tumors. To date, over 100 patients have already been treated using NanoTherm® therapy. In the USA, a pivotal clinical study for the treatment of prostate cancer has been ongoing since July 2018. For more information, please visit: www.magforce.com. Imprint: bit.ly/2C8A8f4